<DOC>
	<DOCNO>NCT02795884</DOCNO>
	<brief_summary>This study perform local multicenter , randomize , phase III clinical study . It compare adjuvant chemotherapy Stage IB-IIIA NSCLC common EGFR mutation ( Exon 19 deletion L858R ) underwent total resection Erlotinib-Intercalation adjuvant chemotherapy chemotherapy alone . The patient randomly assign Intercalation combination chemotherapy regimen chemotherapy alone regimen ratio 1:1 . The treatment regimen arm follow .</brief_summary>
	<brief_title>Adjuvant Erlotinib Intercalating Chemotherapy Adjuvant Chemotherapy Alone NSCLC With Common EGFR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>A screening examination implement within 14 obtain informed consent , treatment start within 14 day randomization subject . Subjects applicable follow criterion eligible inclusion clinical study . Stage IBIIIA Nonsquamous NSCLC ( Based AJCC Version 7 TNM Disease Stages ) Surgically complete resection Confirmed Exon 19 deletion L858R EGFR mutation Complete recovery surgery . The period postoperative randomization 3 week minimum 8 week maximum . Age ≥ 19 year old Patients Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patients pregnant breastfeed Appropriate function bone marrow , liver kidney , assess follow requirement laboratory test conduct within 14 day initial dose study drug : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Total bilirubin ≤ 1.5 time great upper limit normal ALT AST ≤ 2.5 time great upper limit normal Alkaline phosphatase ≤ 2.5 time great upper limit normal INR PTT ≤ 1.5 time great upper limit normal Appropriate renal function : Serum creatinine ≤ 1.25 × upper limit normal , serum creatinine clearance accord CockcroftGault formula ( ) ≥50 mL/min Woman CrCl = ( 140 age [ year old ] ) x weight ( kg ) x 0.85 72 x serum creatinine ( mg/dL ) Man CrCl = ( 140 age [ year old ] ) x weight ( kg ) x 1.00 72 x serum creatinine ( mg/dL ) Patients capable comply clinical study protocol take medication orally Patient hear sufficient explanation sign inform consent form Any subject show follow criterion exclude clinical study : Patient identify T790M mutation Treatable topical treatment ( radiotherapy surgery ) Previous treatment inhibit human epidermal growth factor receptor ( EGFR ) ( e.g . erlotinib , gefitinib , cetuximab , trastuzumab , etc . ) Prior systemic chemotherapy Any prior know hypersensitive reaction study agent CTCAE &gt; grade 2 clinically significant active infection Any known infection Human Immunodeficiency Virus ( HIV ) chronic hepatitis type B type C virus For patient positive chronic hepatitis type B type C virus without elevation AST/ALT , inclusion/exclusion determine discretion investigator . Seizures need treatment ( steroid antiepileptic treatment ) Medical history interstitial lung disease Medical history organ allograft within six month Subjects dialysis A subject diagnose another cancer within 3 year participate clinical study ( treat carcinoma situ cervix , treat skin basal cell carcinoma , treat superficial bladder tumor [ Ta Tis ] applicable ) . For surgically completely resect thyroid cancer , determine discretion investigator . Unstable status would potentially put subject danger would interfere compliance subject clinical study . Treatment investigational product one use clinical study participation clinical study within 4 week prior participation clinical study Pregnant breastfeed woman . The woman childbearing age show negative response serum pregnancy test conduct within 7 day initial administration study drug . Not woman childbearing age , also men give consent use appropriate contraceptive method enter clinical study period clinical study include 30 day last dose study drug . Postmenopausal woman define : 1 . With menstruation least 12 month , age &gt; 50 year old , 2 . With natural menstruation least 6 month level folliclestimulating hormone ( FSH ) postmenopausal range ( &gt; 40 mIU/mL ) age ≤50 year old , 3 . Bilateral oophorectomy Men woman enrol clinical study must use appropriate block contraceptive method prior clinical study . Appropriate contraceptive method include implant combined oral contraceptive agentutilized hormone contraception , intrauterine contraceptive device , bilateral tubal ligation , hysterectomy , vasectomy partner . In addition , use condom require subject his/her partner . Subjects unable swallow oral medication type absorption disorder In addition , investigator determines adequate perform study due serious systemic disease .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>adjuvant treatment</keyword>
</DOC>